Originally published February 2 2005
Celebrex, Bextra ads mislead consumers on dangerous side effects, says FDA
by Mike Adams, the Health Ranger, NaturalNews Editor
The FDA stopped the production of all television and print ads for painkillers Celebrex and Bextra, stating did not emphasize the drugs' health risks to consumers. Both drugs are associated with an increased risk of heart attack. Drug company Pfizer spent $70 million on Celebrex advertisements in the U.S. last year. Few ads were launched for Bextra.
Advertisements for painkillers Celebrex and Bextra were misleading and unsubstantiated, overstating the drugs' benefits and understating the risks, the government said yesterday.
The Food and Drug Administration asked for an immediate halt to all ads for Celebrex, which Pfizer Inc. did last month in advance of the agency's letter.
A study in December found high doses of Celebrex were associated with an increased risk of heart attack.
The letter, sent Monday and released yesterday, details the misleading and unsubstantiated claims in ads for Celebrex and a related drug, Bextra, that appeared on television, in print, on TV infomercials, and in direct-mail brochures.
The government said the claims represent serious violations of federal law.
Pfizer spokeswoman Mariann Caprino told Reuters the company would discuss "appropriate" next steps with the FDA.
New York-based Pfizer spent more than $70 million advertising best-selling Celebrex to US consumers in the first nine months of last year.
It has run minimal consumer ads promoting Bextra.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml